Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: Results from the ROCKET AF trial

European Heart Journal

Volumn 35, Issue 4, 2014, Pages 233-241

  Mahaffey, Kenneth W ^a   Stevens, Susanna R ^b   White, Harvey D ^c   Nessel, Christopher C ^d   Goodman, Shaun G ^e   Piccini, Jonathan P ^b   Patel, Manesh R ^b   Becker, Richard C ^b   Halperin, Jonathan L ^f   Hacke, Werner ^g   Singer, Daniel E ^h   Hankey, Graeme J ⁱ   Califf, Robert M ^j   Fox, Keith A A ^k   Breithardt, Günter ^l  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c AUCKLAND CITY HOSPITAL   (New Zealand)

^d JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^e ST MICHAEL'S HOSPITAL   (Canada)

^f MOUNT SINAI MEDICAL CENTER   (United States)

^g UNIVERSITY OF HEIDELBERG   (Germany)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁱ ROYAL PERTH HOSPITAL   (Australia)

^j DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^l UNIVERSITY HOSPITAL MÜNSTER   (Germany)

more..

Author keywords

Atrial fibrillation; Coronary artery disease; Factor Xa; Myocardial infarction; Outcomes; Rivaroxaban; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; RIVAROXABAN; THIENOPYRIDINE DERIVATIVE; WARFARIN;

AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG SAFETY; EMBOLISM; EMBOLISM PREVENTION; FEMALE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

ATRIAL FIBRILLATION; CORONARY ARTERY DISEASE; FACTOR XA; MYOCARDIAL INFARCTION; OUTCOMES; RIVAROXABAN; WARFARIN;

AGED; ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; DOUBLE-BLIND METHOD; EMBOLISM; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MORPHOLINES; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PYRIDINES; STROKE; THIOPHENES; TICLOPIDINE; TREATMENT OUTCOME; WARFARIN;

EID: 84893046356     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/eht428     Document Type: Article

References (37)

1. Schmitt J, Duray G, Gersh BJ, Hohnloser SH. Atrial fibrillation in acute myocardial infarction: A systematic reviewof the incidence, clinical features and prognostic implications. Eur Heart J 2009;30:1038-1045.
2. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: Amajor contributor to stroke in the elderly. The Framingham study. Arch Intern Med 1987;147:1561-1564.
3. MiyasakaY, Barnes ME, Gersh BJ, Cha SS, Bailey KR, AbhayaratnaWP. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006;114: 119-125.
4. Tsang TS, Miyasaka Y, Barnes ME, Gersh BJ. Epidemiological profile of atrial fibrillation: A contemporary perspective. Prog Cardiovasc Dis 2005;48:1-8.
5. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation 1998; 98:946-952.
6. Miyasaka Y, Barnes ME, Bailey KR, Cha SS, Gersh BJ, Seward JB. Mortality trends in patients diagnosed with first atrial fibrillation: A 21-year community-based study. J Am Coll Cardiol 2007;49:986-992.
7. Ehrlich JR, Nattel S, Hohnloser SH. Atrial fibrillation and congestive heart failure: Specific considerations at the intersection of two common and important cardiac disease sets. J Cardiovasc Electrophysiol 2002;13:399-405.
8. Cha YM, Redfield MM, Shen WK, Gersh BJ. Atrial fibrillation and ventricular dysfunction: A vicious electromechanical cycle. Circulation 2004;109:2839-2843.
9. Wang TJ, LarsonMG, Levy D, Vasan RS, Leip EP, Wolf PA.Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: The Framingham Heart Study. Circulation 2003;107:2920-2925.
10. Rathore SS, Berger AK, Weinfurt KP, Schulman KA, Oetgen WJ, Gersh BJ. Acute myocardial infarction complicated by atrial fibrillation in the elderly: Prevalence and outcomes. Circulation 2000;101:969-974.
11. Roy D, Brugada P, Wellens HJ. Atrial tachycardia facilitating initiation of ventricular tachycardia. Pacing Clin Electrophysiol 1983;6:47-52.
12. Gronefeld GC, MaussO, Li YG, Klingenheben T, Hohnloser SH. Association between atrial fibrillation and appropriate implantable cardioverter defibrillator therapy: Results from a prospective study. J Cardiovasc Electrophysiol 2000;11:1208-1214.
13. HammCW, Bertrand M, Braunwald E. Acute coronary syndrome without ST elevation: Implementation of new guidelines. Lancet 2001;358:1533-1538.
14. Wong CK, White HD, Wilcox RG, Criger DA, Califf RM, Topol EJ, Ohman EM. New atrial fibrillation after acute myocardial infarction independently predicts death: The GUSTO-III experience. Am Heart J 2000;140:878-885.
15. ACCF/AHA Task Force. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. Circulation 2011;123:e269-e367.
16. Guidelines for the management of atrial fibrillation: The task force for the management of atrial fibrillation of the ESC. Eur Heart J 2010;31:2369-2429.
17. 2012 ACCF/AHA focused update on the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction. J Am Coll Cardiol 2012; 60:645-681.
18. Guyatt GH, Akl EA, CrowtherM, Gutterman DD, Schuünemann HJ. Antithrombotic therapy and prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:7S-47S.
19. Faxon DP, Eikelboom JW, Berger PB, Holmes DR Jr, Bhatt DL, Moliterno DJ, Becker RC, Angiolillo DJ. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: A North American perspective: Executive summary. Circ Cardiovasc Interv 2011;4:522-534.
20. Paikin JS, Wright DS, Crowther MA, Mehta SR, Eikelboom JW. Triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents. Circulation 2010; 121:2067-2070.
21. Lamberts M, Olesen JB, Ruwald MH, Hansen CM, Karasoy D, Kristensen SL, Køber L, Torp-Pedersen C, Gislason GH, Hansen ML. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: A nationwide cohort study. Circulation 2012;126:1185-1193.
22. Wong CK, White HD, Wilcox RG, Criger DA, Califf RM, Topol EJ, Ohman EM. Management and outcome of patients with atrial fibrillation during acute myocardial infarction: The GUSTO-III experience. Heart 2002;88:357-362.
23. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-891.
24. Rivaroxaban-once daily, oral, direct factorXainhibition compared with vitamin Kantagonism for prevention of stroke and embolism trial in atrial fibrillation: Rationale and design of the ROCKET AF study. Am Heart J 2010;159:340-347.
25. Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, Hricak V, Barnathan ES, Bordes P, Witkowski A, Markov V, Oppenheimer L, Gibson CM. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): A randomised, double-blind, phase II trial. Lancet 2009;374:29-38.
26. Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, Burton P, Cohen M, Cook-Bruns N, Fox KA, Goto S, Murphy SA, Plotnikov AN, Schneider D, Sun X, Verheugt FW, Gibson CM. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012;366:9-19.
27. Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, Bhatt DL, Goodman S, Verheugt FW, Flather M, Huber K, Liaw D, Husted SE, Lopez-Sendon J, De Caterina R, Jansky P, Darius H, Vinereanu D, Cornel JH, Cools F, Atar D, Leiva-Pons JL, Keltai M, Ogawa H, Pais P, Parkhomenko A, Ruzyllo W, Diaz R, White H, Ruda M, Geraldes M, Lawrence J, Harrington RA, Wallentin L. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011;365: 699-708.
28. Granger CB, Alexander JH, McMurray JV, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365: 981-992.
29. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-1151.
30. Hohnloser SH, Oldgren J, Yang S, Wallentin L, Ezekowitz M, Reilly P, Eikelboom J, Brueckmann M, Yusuf S, Connolly SJ. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY trial. Circulation 2012;125:669-676.
31. Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: Meta-Analysis of noninferiority randomized controlled trials. Arch Intern Med 2012;172:397-402.
32. Jacobs JM, Stessman J. Dabigatran: Dowe have sufficient data?: Comment on 'Dabigatran association with higher risk of acute coronary events'. Arch Intern Med 2012;172: 403-404.
33. Dans AL, Connolly SJ, Wallentin L, Yang S, Nakamya J, Brueckmann M, Ezekowitz J, Oldgren J, EikelboomJW, Reilly PA, Yusuf S. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the randomized evaluation of long-Term anticoagulation therapy (RE-LY) trial. Circulation 2013;127:634-640.
34. Lip GY, Huber K, Andreotti F, Arnesen H, Airaksinen JK, Cuisset T, Kirchhof P, Marín F. Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: Executive summary-A Consensus Document of the European Society of Cardiology Working Group on Thrombosis. Eur Heart J 2010;31:1311-1318.
35. Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman JP, Adriaenssens T, Vroliz M, Heestermans AA, Vis MM, Tijsen JG, van't Hof AW, ten Berg JM. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: An open-label, randomised, controlled trial. Lancet 2013;381:1107-1115.
36. Triple Therapy in Patients onOral Anticoagulation After Drug Eluting Stent Implantation (ISAR-TRIPLE) (NCT00776633). ClinicalTrials.govWeb site. http://clinicaltrials. gov/ct2/show/NCT00776633?term=NCT00776633&rank=1 (October 3, 2012).
37. Anticoagulation in Stent Intervention (MUSICA-2) (NCT01141153). ClinicalTrials- govWeb site. http://clinicaltrials.gov/ct2/show/NCT01141153? term=NCT01141153 &rank=1 (October 3, 2012).